Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
AIM: The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. METHODS: An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and expenditure of different proton pump inhibitors (PPIs) and statins between 2001 and 2007, alongside different reforms to enhance prescribing efficiency. Utilization was converted to defined daily doses (DDDs) and expenditures were converted to euros. Demand-side measures were collated under the '4 Es'--education, engineering, economics and enforcement--to enable comparisons on the nature and intensity of reforms between countries. RESULTS: There were considerable differences in the utilization of generics and patent-protected PPIs and statins among Western European countries. Decreased utilization of omeprazole and simvastatin, alongside increased utilization of esomeprazole, atorvastatin and rosuvastatin, was seen in countries with limited demand-side measures to counteract commercial pressures. Prescribing restrictions, or a combination of education, prescribing targets and financial incentives, had the greatest influence on enhancing the utilization of omeprazole and simvastatin. For example, there was a threefold reduction in the utilization of atorvastatin in Austria following prescribing restrictions. Multiple demand-side interventions generally had a greater influence than single interventions, with the impact appearing additive. Multiple interventions coupled with initiatives to lower prices of generics considerably enhanced prescribing efficiency. CONCLUSION: This cross-national study has demonstrated considerable variation in the utilization and expenditure of PPIs and statins across Europe, providing opportunities to further improve prescribing efficiency. The '4 Es' do provide an understandable methodology to document and compare the influence of different demand-side measures, with the influence varying by their extent and intensity. Further reforms are essential given current financial pressures. Consequently, further research will concentrate on the potential to develop a scoring system to help predict the possible impact of different demand-side measures on future utilization patterns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From best evidence to best practice: effective implementation of change in patients' care
Grol, R., & Grimshaw, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14546-1 · Cited by 4,531
Effectiveness and efficiency of guideline dissemination and implementation strategies
Grimshaw, J., Thomas, R., MacLennan, G., Fraser, C., Ramsay, C., Vale, L., Whitty, P., Eccles, M., Matowe, L., Shirran, L., et al. (2004) · Health Technology Assessment · doi:10.3310/hta8060 · Cited by 3,044
Bero, L. A., Grilli, R., Grimshaw, J. M., Harvey, E., Oxman, A. D., & Thomson, M. A. (1998) · BMJ · doi:10.1136/bmj.317.7156.465 · Cited by 2,396
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Experimental and quasi-experimental designs for evaluating guideline implementation strategies
Grimshaw, J. (2000) · Family Practice · doi:10.1093/fampra/17.suppl_1.s11 · Cited by 382
New medicines in primary care: a review of influences on general practitioner prescribing
Mason, A. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00875.x · Cited by 77
Cited by
Irrational Use of Medicines—A Summary of Key Concepts
Ofori-Asenso, R., & Agyeman, A. (2016) · Pharmacy · doi:10.3390/pharmacy4040035 · Cited by 287
Medicine Shortages: Gaps Between Countries and Global Perspectives
Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00763 · Cited by 147
Self-citationBochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00942 · Cited by 112
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationDisinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Parkinson, B., Sermet, C., Clement, F., Crausaz, S., Godman, B., Garner, S., Choudhury, M., Pearson, S.-A., Viney, R., Lopert, R., et al. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0293-8 · Cited by 93
Self-citation
Metadata
- Authors
- Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., Garuoliene, K., Herholz, H., Joppi, R., Kalaba, M., Laius, O., McGinn, D., Samaluk, V., Sermet, C., Schwabe, U., Teixeira, I., Tilson, L., Tulunay, F. C., Vlahović-Palčevski, V., Wendykowska, K., Wettermark, B., Zara, C., & Gustafsson, L. L.
- Venue
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2010-12
- Volume
- 10
- Issue
- 6
- Pages
- 707-722
- ISSN
- 1473-7167 (ISSN-L)
- 1744-8379
- OpenAlex
- W2160675720
- Cited by
- 153
- References
- 7
- FWCI
- 39.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. https://app.cochat.ai/papers/10.1586/erp.10.72
- The paper
- Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., Garuoliene, K., Herholz, H., Joppi, R., Kalaba, M., Laius, O., McGinn, D., Samaluk, V., Sermet, C., Schwabe, U., Teixeira, I., Tilson, L., Tulunay, F. C., Vlahović-Palčevski, V., . . . Gustafsson, L. L. (2010). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1586/erp.10.72
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.